The stock of The Medicines Company (NASDAQ:MDCO) is a huge mover today! About 808,339 shares traded hands. The Medicines Company (NASDAQ:MDCO) has risen 3.42% since March 7, 2016 and is uptrending. It has underperformed by 4.18% the S&P500.
The move comes after 8 months positive chart setup for the $2.59B company. It was reported on Oct, 10 by Barchart.com. We have $57.10 PT which if reached, will make NASDAQ:MDCO worth $1.45B more.
Analysts await The Medicines Company (NASDAQ:MDCO) to report earnings on November, 1. They expect $-1.48 earnings per share, down 64.44% or $0.58 from last year’s $-0.9 per share. After $-0.84 actual earnings per share reported by The Medicines Company for the previous quarter, Wall Street now forecasts 76.19% negative EPS growth.
The Medicines Company (NASDAQ:MDCO) Ratings Coverage
Out of 4 analysts covering The Medicines Co (NASDAQ:MDCO), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. The Medicines Co has been the topic of 11 analyst reports since August 28, 2015 according to StockzIntelligence Inc. The stock of The Medicines Company (NASDAQ:MDCO) has “Buy” rating given on Saturday, August 29 by JP Morgan. On Monday, November 16 the stock rating was maintained by RBC Capital Markets with “Outperform”. The stock has “Hold” rating given by Jefferies on Friday, August 28. The firm has “Buy” rating given on Monday, March 21 by Chardan Capital Markets. The stock of The Medicines Company (NASDAQ:MDCO) earned “Buy” rating by Chardan Capital Markets on Wednesday, November 4. The company was maintained on Monday, August 31 by Leerink Swann. The firm earned “Outperform” rating on Monday, August 31 by RBC Capital Markets. The firm earned “Market Perform” rating on Monday, August 31 by Oppenheimer.
According to Zacks Investment Research, “Medicines Company acquires, develops and commercializes biopharmaceutical products in late stages of development. U.S. Food and Drug Administration intends to approve its first product, Angiomax, for use in the treatment of patients with unstable angina undergoing coronary balloon angioplasty. The company is also developing Angiomax for additional potential applications for use in the treatment of ischemic heart disease, a condition which occurs when organs receive an inadequate supply of oxygen as a result of decreased blood flow.”
Insitutional Activity: The institutional sentiment increased to 1.27 in Q2 2016. Its up 0.14, from 1.13 in 2016Q1. The ratio increased, as 20 funds sold all The Medicines Company shares owned while 54 reduced positions. 25 funds bought stakes while 69 increased positions. They now own 81.19 million shares or 0.45% less from 81.56 million shares in 2016Q1.
Prudential Finance holds 0.01% or 176,091 shares in its portfolio. Falcon Edge Cap Limited Partnership accumulated 1.58% or 640,000 shares. Moreover, Teachers has 0.02% invested in The Medicines Company (NASDAQ:MDCO) for 306,060 shares. Morgan Stanley has 0% invested in the company for 31,438 shares. Royal Commercial Bank Of Canada has 0% invested in the company for 36,838 shares. National Bank Of New York Mellon reported 813,652 shares or 0.01% of all its holdings. Jennison Associate Lc has invested 0.03% of its portfolio in The Medicines Company (NASDAQ:MDCO). Teachers Retirement Of The State Of Kentucky has 0.11% invested in the company for 257,090 shares. Gemmer Asset Mgmt holds 0% of its portfolio in The Medicines Company (NASDAQ:MDCO) for 133 shares. Kornitzer Cap Mgmt Incorporated Ks has 1.14 million shares for 0.69% of their US portfolio. Legal And General Gp Public Limited Com accumulated 0% or 14,883 shares. Aperio Group Inc Limited Liability Com last reported 0.01% of its portfolio in the stock. Envestnet Asset Management last reported 0% of its portfolio in the stock. Signpost Capital Advisors Lp, a New York-based fund reported 219,998 shares. Corvex Management L P accumulated 3.09 million shares or 1.4% of the stock.
Insider Transactions: Since May 11, 2016, the stock had 3 insider buys, and 8 selling transactions for $10.34 million net activity. The insider Cox Christopher T bought $1.74M. MEANWELL CLIVE sold 20,000 shares worth $800,000. $510,998 worth of The Medicines Company (NASDAQ:MDCO) shares were sold by WYATT ELIZABETH H S. Another trade for 300,000 shares valued at $10.10M was bought by ESHELMAN FREDRIC N. The insider CROUSE WILLIAM sold 15,000 shares worth $527,295. $555,000 worth of The Medicines Company (NASDAQ:MDCO) shares were sold by Spigelman Melvin K. 10,000 shares were sold by Savage Robert G., worth $369,500.
More important recent The Medicines Company (NASDAQ:MDCO) news were published by: Foxbusiness.com which released: “Why The Medicines Company’s Share Price Got Sick Today” on October 06, 2016, also Reuters.com published article titled: “BRIEF-The Medicines Company says provides update on PCSK9si study”, Businesswire.com published: “The Medicines Company Provides Progress Update on Ongoing ORION-1 Study of PCSK9si” on October 05, 2016. More interesting news about The Medicines Company (NASDAQ:MDCO) was released by: Fiercebiotech.com and their article: “The Medicines Company sees shares slide on key trial not stopping early” with publication date: August 31, 2016.
MDCO Company Profile
The Medicines Company, incorporated on July 31, 1996, is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). The Company’s pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Firm sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. The Firm sells over three of its acute care generic products, including midazolam, ondansetron and rocuronium.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.